Merck's heart failure drug misses trial goals

June 5, 2009

(AP) -- Merck and Co. said Friday its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo.

The company said rolofylline did not reach its primary or secondary goals in the late-stage trial. Based on the results, Merck said it no longer plans to ask the to approve the drug candidate this year.

The trial also showed that 30 mg of rolofylline did not reduce the risk of death or hospitalization due to heart or kidney problems 60 days after treatment, and that it did not reduce kidney impairment.

Merck is still analyzing study data from the study, which is called PROTECT, and it will present full results from the 2,033-patient trial at a medical conference later this year.

In morning trading, Merck shares fell 64 cents, or 2.4 percent, to $25.94.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Study: Vioxx poses even short-term risks

Related Stories

Study: Vioxx poses even short-term risks

May 3, 2006

A Montreal study raises questions about even short-term use of the pain drug Vioxx and may harm Merck & Co.'s defense against 11,500 lawsuits, a report said.

FDA pans Merck's new pain pill

April 13, 2007

The U.S. Food and Drug Administration has rejected Merck's bid to sell the pain medication Arcoxia in the United States.

Merck's Vioxx cases drag on

August 21, 2007

Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.

Trials find no benefits of Zetia

January 15, 2008

The U.S. makers of the cholesterol-lowering drug Zetia say a clinical trial failed to identify any medical benefits of the medication.

FDA to review Vytorin results

January 26, 2008

The U.S. Food and Drug Administration said it is conducting a review of the cholesterol drug Vytorin based on preliminary results from a recent study.

AstraZeneca, Merck collaborate on cancer treatment

June 1, 2009

(AP) -- AstraZeneca PLC and Merck & Co. said Monday they will jointly develop a pair of drugs meant to hit cancer with a one-two punch, part of a growing trend of combination cancer treatments.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

deatopmg
1 / 5 (1) Jun 05, 2009
Did the silly study name reflect the outcome for the patients or the bottom line.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.